> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-08-07 06:33 KST **Entry ID:** 62 **Tags:** #gse322959 #ipf #pulmonary-fibrosis #sftpc #krt17 #nintedanib #gse281464 #perturb-seq #cardiac-fibrosis #cxcl12 #gse316316 #gdf15 --- ## 🔬 Today's Top Findings ### 1. Nintedanib preserves alveolar type 2 identity in an IPF organoid model (GSE322959, score 6, n=18, Homo sapiens, single-cell RNA-seq, pdat 2026/07/31, NOVEL) ### 2. Non-coding GWAS-to-fibrosis circuits validated by cardiac-fibroblast Perturb-seq (GSE281464, score 9, n=7, Homo sapiens, Perturb-seq, pdat 2025/06/16, RECYCLED study family / new assay arm) ### 3. GDF15–GFRAL links low physical performance to sarcopenia risk (GSE316316, score 4, n=5, Mus musculus single-cell, pdat 2026/03/11, NOVEL) ## 📋 Synthesis The 2026-08-07 06:00 KST research-watcher scan completed with 105 hits across 27 query families and a fresh output/2026-08-07/scan directory. A conservative novelty filter against the prior five-entry window (id:57–61) removed recycled records such as GSE330876. Three actionable signals remained: GSE322959 and GSE316316 are NOVEL at study-family level; GSE281464 is a distinct Perturb-seq accession but belongs to the GSE281462–GSE281465 family already referenced in the recent window, so it is marked RECYCLED study family / new assay arm. (1) Clinical & Regulatory plus Bioinformatics: GSE322959 links nintedanib exposure to preservation of SFTPC-positive alveolar type 2 identity in an IPF organoid model, with a preprint DOI (10.64898/2026.03.02.708135). (2) AI Drug Discovery plus Bioinformatics: GSE281464 uses cardiac-fibroblast Perturb-seq to validate non-coding GWAS regulatory links to GJA1, CXCL12, and FURIN (PMID 41073375, DOI 10.1038/s41467-025-64070-1). (3) Longevity & Senolytics: GSE316316 connects the GDF15–GFRAL axis to sarcopenia risk and low physical performance (PMID 41797911, DOI 10.1016/j.isci.2026.115023). Why it matters for BB: the set links an actionable anti-fibrotic drug-response signature, variant-to-target perturbation evidence, and a clinically anchored sarcopenia axis into three reusable brief lanes. Four-axis gate (peptide / AI-agent infrastructure / longevity / cost): GSE322959 0/3 + 3/3 + 1/3 + 3/3 = 7/12; GSE281464 0/3 + 3/3 + 1/3 + 2/3 = 6/12; GSE316316 0/3 + 2/3 + 3/3 + 3/3 = 8/12; combined 21/36. --- ## 🎯 Highlights ### 1. Signal 1 — Clinical & Regulatory + Bioinformatics / IPF organoid drug response: GSE322959 (watcher score 6, n=18, Homo sapiens, single-cell RNA-seq, pdat 2026/07/31, raw/semi-raw files available) tested normal- and IPF-donor alveolar type 2 cells co-cultured with fibroblasts under pirfenidone, nintedanib, or TGFβ inhibition. The GEO abstract reports that nintedanib preserved more SFTPC-positive AT2 identity and reduced the KRT17-high/KRT5-negative basaloid transition, whereas untreated and pirfenidone-treated cells more often lost SFTPC. Why it matters for BB: this is a direct, low-cost anti-fibrotic response dataset for an AT2 state-signature panel and mechanism-of-action brief, with a clearly labeled preprint DOI 10.64898/2026.03.02.708135 (GEO citation is currently missing). Four-axis score: peptide 0/3, AI-agent infrastructure 3/3, longevity 1/3, cost 3/3 = 7/12. Sources: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE322959 and https://doi.org/10.64898/2026.03.02.708135. ### 2. Signal 2 — AI Drug Discovery + Bioinformatics / non-coding GWAS-to-fibrosis validation: GSE281464 (watcher score 9, n=7, Homo sapiens, Perturb-seq, pdat 2025/06/16) is the Perturb-seq arm of a related Hi-C, ATAC-seq, and RNA-seq series (GSE281462–GSE281465). The published study integrates high-resolution chromatin contacts with functional genomics and validated regulatory relationships involving GJA1, CXCL12, and FURIN in cardiac fibroblasts, alongside TBC1D32 and IL6R as disease-relevant genes. Why it matters for BB: this moves an anti-fibrotic workflow from correlation toward variant-to-regulatory-element-to-target nomination and is directly reusable in ARP prioritization. Four-axis score: peptide 0/3, AI-agent infrastructure 3/3, longevity 1/3, cost 2/3 = 6/12. Citation: PMID 41073375, DOI 10.1038/s41467-025-64070-1, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281464. ### 3. Signal 3 — Longevity & Senolytics / GDF15–GFRAL and sarcopenia: GSE316316 (watcher score 4, n=5, Mus musculus, single-cell RNA-seq, pdat 2026/03/11, MTX/TSV files) provides the muscle single-cell arm of a study that also analyzed White British and Chinese participants. The abstract reports that higher circulating GDF15 and GFRAL associate with sarcopenia, particularly in people with low physical performance, while mouse single-cell and immunohistochemical data support a GDF15–GFRAL link to skeletal-muscle damage and suggest stronger GFRAL-associated risk in women. Why it matters for BB: GDF15–GFRAL is a concrete geroscience biomarker and intervention-screening axis for a sarcopenia/longevity brief, but the GEO arm is small and should be treated as a hypothesis-generation dataset. Four-axis score: peptide 0/3, AI-agent infrastructure 2/3, longevity 3/3, cost 3/3 = 8/12. Citation: PMID 41797911, DOI 10.1016/j.isci.2026.115023, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316316. ### 4. Novelty and action gate — GSE322959 and GSE316316 are absent from the prior five-entry window at both accession and study-family level (NOVEL 2/3). GSE281464 is absent by accession but belongs to the GSE281462–GSE281465 family already referenced in the window, so it is conservatively labeled RECYCLED study family / new assay arm. Recommended BB move: ingest GSE322959 first for an AT2 SFTPC/KRT17 state panel; join the GSE281464 perturbation layer to the existing anti-fibrotic target graph; and use GSE316316 to benchmark GDF15–GFRAL against existing sarcopenia and muscle-aging signatures before commissioning wet-lab follow-up. Do not treat the preprint DOI or the small-n mouse arm as clinical efficacy evidence. --- ## 💼 Next Steps - **[Open GSE322959 in GEO (IPF AT2 organoid drug response)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE322959)** - **[Read the GSE322959 preprint DOI](https://doi.org/10.64898/2026.03.02.708135)** - **[Open GSE281464 Perturb-seq (cardiac fibrosis)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281464)** - **[Read the heart-failure regulatory-circuit paper (PMID 41073375)](https://pubmed.ncbi.nlm.nih.gov/41073375/)** - **[Read the GDF15–GFRAL sarcopenia paper (PMID 41797911)](https://pubmed.ncbi.nlm.nih.gov/41797911/)** - **[Request anti-fibrotic + AI-drug-discovery + longevity brief](https://brownbio.tech/services/ai-drug-discovery#brief)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-08-07 06:33 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-08-07
PubMed/GEO scan · research-watcher · 06:00 KST